This paper aimed to screen cholesterol analogues as membrane stabilizers of liposomes from botanical sterols, including beta-sitosterol, stigmasterol, ergosterol and lanosterol. Liposomes containing four kinds of sterols were prepared

and evaluated in vitro AL3818 clinical trial and in vivo as oral delivery system of insulin. Liposomes containing beta-sitosterol (Si-Lip), stigmasterol (St-Lip) and lanosterol (La-Lip) was found not to protect insulin against degradation. Only 10% of the initial insulin in liposomes was preserved after a 30 min exposure to simulated gastric fluids. However, the protective ability of liposomes containing ergosterol (Er-Lip) was similar to that of liposomes containing sodium glycocholate (Sgc-Lip) and superior to that of liposomes containing cholesterol (Ch-Lip). In addition, the blood glucose level can decrease to about 50% of initial GDC 0032 inhibitor level after oral Er-Lip which was significantly superior to the in vivo performance of Si-Lip and Ch-Lip and similar to Sgc-Lip. Er-Lips of ergosterol/ phospholipids ratios of 1:4 or 1:6 exerts

more pronounced protective ability of insulin in simulated gastrointestinal fluids and hypoglycemic effects in rats than other formulations. Furthermore, Er-Lips exerted low toxicity to Caco-2 cells through a cell viability study. Meahwhile, insulin permeability was 4-Hydroxytamoxifen clinical trial significantly increased across Caco-2 monolayers by encapsulating in Er-Lip. It was concluded that ergosterol could be used as a substitute for cholesterol and bile salt derivatives in liposomes to enhance oral bioavailability of insulin. (C) 2015 Elsevier B.V. All rights reserved.”
“The optimal duration of clopidogrel administration

after percutaneous coronary intervention (PCI) remains unknown. Clopidogrel is currently recommended for minimums of I and 12 months after bare-metal stent and drug-eluting stent implantation, respectively. To determine the impact of clopidogrel discontinuation 1 year after PCI, the outcomes of 530 consecutive patients who underwent PCI from January 2004 to July 2006, were free of cardiovascular events for 6 months after PCI, and had follow-up available for > 12 months were examined. The outcomes of patients who received clopidogrel for >= 1 year were compared with those of patients who received it for <1 year. The mean age was 65 +/- 9 years. Patients often presented with acute coronary syndromes (57%), and 85% received drug-eluting stents. Clopidogrel was used for >= 1 year and for <1 year in 341 and 1,89 patients, respectively. During a mean follow-up period of 2.4 +/- 0.8 years, 40 patients (8%) died. 21 (4%) had acute myocardial infarctions, and 89 (17%) underwent repeat coronary revascularization.